Trial Success With Rare Disease Drug Nets Bonuses for Two BioMarin Pharmaceutical Inc. (BMRN) Execs
11/29/2012 8:11:53 AM
BioMarin Pharmaceutical Inc.'s solid Phase III trial of an experimental treatment for a rare crippling disease netted two of its executives hefty cash bonuses. Dr. Henry Fuchs, chief medical officer of the Novato company (NASDAQ: BMRN), received a $100,000 bonus, the company said Wednesday in a Securities and Exchange Commission filing. Robert Baffi, the executive vice president of technical operations, scored a $50,000 bonus. BioMarin said that its board of directors' compensation committee awarded the bonuses Monday "to reward them for their extraordinary efforts" on the late-stage trial of the drug BMS-110 for paitnets with mucopolysaccharidosis type IVA, or MPS IVA.